Elbasvir
Tags:
drug
small molecule
PubChem: 71661251 71661251 DrugBank: DB11574 DB11574 Related interactions
Related publications
Title
Author
Type
Drug Repurposing of Approved Drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for Combating COVID19 Vishal Mevada, Pravin Dudhagara, Himani Gandhi, Nilam Vaghamshi, Urvisha Beladiya, Rajesh Patel
Research
Comparative Computational Study of SARS-CoV-2 Receptors Antagonists from Already Approved Drugs Micael Davi, Lima de Oliveira, Kelson Mota, Teixeira de Oliveira
Research
Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study Wang J
Research
Combined Deep Learning and Molecular Docking Simulations Approach Identifies Potentially Effective FDA Approved Drugs for Repurposing Against SARS-CoV-2 Muhammad U Anwar, Farjad Adnan, Asma Abro, Rayyan A Khan, Asad U Rehman, Muhammad Osama, Saad Javed, Ahmadullah Baig , Muhammad R Shabbir, Muhammad Z Assir
Research
Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste James T. Gordy, Kaushiki Mazumdar, Noton K. Dutta
Other
Computational Target-Based Drug Repurposing of Elbasvir, an Antiviral Drug Predicted to Bind Multiple SARS-CoV-2 Proteins Meenakshisundaram Balasubramaniam, Robert J. Shmookler Reis
Research
Rationale Based Selection and Prioritization of Antiviral Drugs for COVID-19 Management Rakesh Joshi, Ashok P. Giri, Mahesh J. Kulkarni, Mahesh Gupta, Savita Verma, Dhruva Chaudhary, Narendra Deshmukh, Anita Chugh
Research
CSF3 Is a Potential Drug Target for the Treatment of COVID-19 Fang Chao, Mei Jie, Tian Huixiang, Liou Yu-Ligh, Rong Dingchao, Zhang Wei, Liao Qianjin, Wu Nayiyuan
Research
Drug repositioning to target NSP15 protein on SARS-CoV-2 as possible COVID-19 treatment Yudibeth Sixto-López Ph. D., Marlet Martínez-Archundia
Research
Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2. Anwaar, Muhammad U.Adnan, FarjadAbro, AsmaKhan, Rayyan A.Rehman, Asad U.Osama, MuhammadRainville, ChristopherKumar, SureshSterner, DavidJaved, SaadJamal, Syed B.Baig, AhmadullahShabbir, Muhammad R.Ahsan, WasehButt, Tauseef R.Assir, Muhammad Z.
Research
Target
Target affiliation
Drug
Type
Result
Target
Target affiliation
Drug
Type
Result
Name
Synonyms
Genes
Origin
Name
Synonyms
Genes
Origin
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Title
Authors
DOI
Source
Article type
Date
Title
Authors
DOI
Source
Article type
Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
CORDITE (CORona Drug InTEractions database) collects and aggregates data from PubMed, MedRxiv, BioRxiv, ChemRxiv and PMC for SARS-CoV-2. Its main focus is set on drug interactions either addressing viral proteins or human proteins that could be used to treat COVID.
It collects and provides up-to-date information on computational predictions, in vitro, as well as in vivo study data.
The information provided is for research only and we cannot guarantee the correctness of the data.
Please contact dominik.heider@uni-muenster.de for further information.
Programmable access
There is an open API for access programmatically to the database. The API will print a JSON output:
Interactions
https://cordite-api.uni-muenster.de/api.php?action=list&table=interaction Targets
https://cordite-api.uni-muenster.de/api.php?action=list&table=target Drugs
https://cordite-api.uni-muenster.de/api.php?action=list&table=drug Publications
https://cordite-api.uni-muenster.de/api.php?action=list&table=publication Clinical trials
https://cordite-api.uni-muenster.de/api.php?action=list&table=clinical_trial
